Free Trial

Biohaven (BHVN) Competitors

Biohaven logo
$13.60 -0.09 (-0.69%)
As of 03:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BHVN vs. TLX, AXSM, LNTH, PCVX, CYTK, MRUS, KRYS, MTSR, RNA, and AKRO

Should you be buying Biohaven stock or one of its competitors? The main competitors of Biohaven include Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), Lantheus (LNTH), Vaxcyte (PCVX), Cytokinetics (CYTK), Merus (MRUS), Krystal Biotech (KRYS), Metsera (MTSR), Avidity Biosciences (RNA), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry.

Biohaven vs. Its Competitors

Biohaven (NYSE:BHVN) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

Telix Pharmaceuticals' return on equity of 0.00% beat Biohaven's return on equity.

Company Net Margins Return on Equity Return on Assets
BiohavenN/A -257.07% -164.01%
Telix Pharmaceuticals N/A N/A N/A

In the previous week, Biohaven had 6 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 23 mentions for Biohaven and 17 mentions for Telix Pharmaceuticals. Biohaven's average media sentiment score of 0.11 beat Telix Pharmaceuticals' score of 0.11 indicating that Biohaven is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biohaven
3 Very Positive mention(s)
1 Positive mention(s)
16 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
Telix Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
3 Very Negative mention(s)
Neutral

Telix Pharmaceuticals has higher revenue and earnings than Biohaven.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiohavenN/AN/A-$846.42M-$9.36-1.42
Telix Pharmaceuticals$516.72M9.24$32.93MN/AN/A

Biohaven currently has a consensus price target of $58.46, indicating a potential upside of 338.74%. Telix Pharmaceuticals has a consensus price target of $22.33, indicating a potential upside of 58.22%. Given Biohaven's stronger consensus rating and higher possible upside, analysts clearly believe Biohaven is more favorable than Telix Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biohaven
0 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
3.07
Telix Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

88.8% of Biohaven shares are owned by institutional investors. 16.0% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Biohaven beats Telix Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Get Biohaven News Delivered to You Automatically

Sign up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BHVN vs. The Competition

MetricBiohavenMED IndustryMedical SectorNYSE Exchange
Market Cap$1.36B$3.04B$5.71B$21.10B
Dividend YieldN/A2.40%4.60%3.58%
P/E Ratio-1.4221.1328.0727.85
Price / SalesN/A338.95459.4759.34
Price / CashN/A43.2336.5523.00
Price / Book3.188.278.614.68
Net Income-$846.42M-$55.19M$3.24B$994.49M
7 Day Performance-5.09%5.50%3.83%1.53%
1 Month Performance-7.08%17.25%10.40%5.79%
1 Year Performance-66.86%4.61%34.13%11.35%

Biohaven Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BHVN
Biohaven
2.3038 of 5 stars
$13.59
-0.7%
$58.46
+330.2%
-64.5%$1.39BN/A-1.45239News Coverage
TLX
Telix Pharmaceuticals
N/A$16.50
+1.7%
$22.33
+35.4%
N/A$5.58B$516.72M0.00N/ANews Coverage
Analyst Revision
High Trading Volume
AXSM
Axsome Therapeutics
4.7409 of 5 stars
$109.68
-1.8%
$172.33
+57.1%
+23.2%$5.40B$385.69M-19.01380Analyst Revision
LNTH
Lantheus
4.6964 of 5 stars
$71.56
+2.0%
$131.20
+83.3%
-37.6%$4.95B$1.53B20.33700Positive News
PCVX
Vaxcyte
1.8143 of 5 stars
$35.64
-1.6%
$136.50
+283.0%
-57.4%$4.60BN/A-8.93160News Coverage
Positive News
CYTK
Cytokinetics
4.2146 of 5 stars
$36.96
-0.7%
$70.92
+91.9%
-34.3%$4.41B$18.47M-6.99250News Coverage
MRUS
Merus
1.9941 of 5 stars
$62.37
-1.4%
$84.64
+35.7%
+20.1%$4.32B$36.13M-15.2937Upcoming Earnings
KRYS
Krystal Biotech
4.8848 of 5 stars
$148.09
+0.4%
$213.75
+44.3%
-27.4%$4.28B$290.52M35.60210News Coverage
Analyst Forecast
MTSR
Metsera
N/A$39.91
-6.6%
$55.00
+37.8%
N/A$4.19BN/A0.0081Lockup Expiration
Gap Up
RNA
Avidity Biosciences
2.159 of 5 stars
$34.02
+0.8%
$66.35
+95.0%
-25.6%$4.10B$8.93M-11.34190News Coverage
AKRO
Akero Therapeutics
3.7794 of 5 stars
$51.38
-1.3%
$82.50
+60.6%
+88.3%$4.10BN/A-26.3530Positive News

Related Companies and Tools


This page (NYSE:BHVN) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners